PAP
CORT icon

Persistent Asset Partners’s Corcept Therapeutics CORT Stock Holding History

Persistent Asset Partners’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,528
Closed -$153K – 837
2026
Q1 		$102K Sell
2,528
-23,304
-90% -$871K 0.04% 237
2025
Q4 		$899K Buy
+25,832
New +$2.03M 0.4% 71

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Persistent Asset Partners's CORT Position: Q2 2026 in Review

Persistent Asset Partners sold out of Corcept Therapeutics (CORT) in Q2 2026, closing a stake of 2,528 shares — an estimated $153K sold.

Persistent Asset Partners first reported a position in CORT in Q4 2025 and held it in 2 quarters. The position peaked at $899K in Q4 2025. 423 funds tracked by Wall St. Rank hold CORT as of Q2 2026.

  • Persistent Asset Partners reported no remaining Corcept Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Persistent Asset Partners sold 2,528 Corcept Therapeutics shares in Q2 2026, an estimated $153K.
  • Persistent Asset Partners first reported a position in Corcept Therapeutics in Q4 2025 and held it in 2 quarters.
  • Persistent Asset Partners's Corcept Therapeutics position peaked at $899K in Q4 2025.
  • 423 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q2 2026.

Based on Persistent Asset Partners's 13F filing for Q2 2026, filed 7 Aug 2026.